PLoS ONE (Jan 2013)

CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model.

  • Lam Quoc Bao,
  • Nguyen Tien Huy,
  • Mihoko Kikuchi,
  • Tetsuo Yanagi,
  • Masachika Senba,
  • Mohammed Nasir Shuaibu,
  • Kiri Honma,
  • Katsuyuki Yui,
  • Kenji Hirayama

DOI
https://doi.org/10.1371/journal.pone.0064836
Journal volume & issue
Vol. 8, no. 5
p. e64836

Abstract

Read online

In African endemic area, adults are less vulnerable to cerebral malaria than children probably because of acquired partial immunity or semi-immune status. Here, we developed an experimental cerebral malaria (ECM) model for semi-immune mice. C57BL/6 (B6) mice underwent one, two and three cycles of infection and radical treatment (1-cure, 2-cure and 3-cure, respectively) before being finally challenged with 10(4) Plasmodium berghei ANKA without treatment. Our results showed that 100% of naïve (0-cure), 67% of 1-cure, 37% of 2-cure and none of 3-cure mice succumbed to ECM within 10 days post challenge infection. In the protected 3-cure mice, significantly higher levels of plasma IL-10 and lower levels of IFN-γ than the others on day 7 post challenge infection were observed. Major increased lymphocyte subset of IL-10 positive cells in 3-cure mice was CD5(-)CD19(+) B cells. Passive transfer of splenic CD19(+) cells from 3-cure mice protected naïve mice from ECM. Additionally, aged 3-cure mice were also protected from ECM 12 and 20 months after the last challenge infection. In conclusion, mice became completely resistant to ECM after three exposures to malaria. CD19(+) B cells are determinants in protective mechanism of semi-immune mice against ECM possibly via modulatory IL-10 for pathogenic IFN-γ production.